⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10956683 | 0.80 | — | — | |
| SCHEMBL19511124 | 0.74 | — | — | |
| SCHEMBL1968495 | 0.65 | — | — | |
| SCHEMBL4038269 | 0.56 | — | — | |
| SCHEMBL5281139 | 0.55 | — | — | |
| SCHEMBL29002963 | 0.48 | MEN1 (0.33) | — | |
| SCHEMBL13738003 | 0.48 | MEN1 (0.33) | — | |
| Calcium Chloride SCHEMBL29089243 | 0.46 | — | — | |
| Water SCHEMBL8881776 | 0.46 | MEN1 (0.31) | — | |
| Nitric Acid SCHEMBL28233455 | 0.44 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107567443-B | Biaryl derivatives as GPR120 agonists | 株式会社LG化学 | 2023-04-28 | — | — | CN | disclosed |
| CN-115925679-A | Biaryl derivatives as GPR120 agonists | 株式会社LG化学 | 2023-04-07 | — | — | CN | disclosed |
| EP-3239143-B1 | BIARYL DERIVATIVE AS GPR120 AGONIST | LG CHEMICAL LTD (KR) | 2023-03-22 | — | — | EP | disclosed |
| US-20220135574-A1 | BIARYL DERIVATIVE AS GPR120 AGONIST | LG CHEM, LTD. (KR) | 2022-05-05 | — | — | US | disclosed |
| US-11261186-B2 | Biaryl derivative as GPR120 agonist | LG CHEM. LTD. (KR) | 2022-03-01 | — | — | US | disclosed |
| US-20170349594-A1 | BIARYL DERIVATIVE AS GPR120 AGONIST | LG CHEM, LTD. (KR) | 2017-12-07 | — | — | US | disclosed |
| EP-3239143-A2 | BIARYL DERIVATIVE AS GPR120 AGONIST | LG Chem, Ltd. (KR) | 2017-11-01 | — | — | EP | disclosed |
| US-20150011545-A1 | Chemical Compounds - 759 | ASTRAZENECA AB (SE) | 2015-01-08 | — | — | US | disclosed |
| US-20140155394-A1 | Chemical Compounds - 759 | ASTRAZENECA AB (SE) | 2014-06-05 | — | — | US | disclosed |
| US-8486966-B2 | 9-(pyrazol-3-yl)-9H-purine-2-amine and 3-(pyrazol-3-yl) -3H-imidazo[4,5-B] pyridin-5-amine derivatives and their use for the treatment of cancer | ASTRAZENECA AB (SE) | 2013-07-16 | — | — | US | disclosed |
| US-20100093734-A1 | CYTOKINE INHIBITORS | ITHERX PHARMACEUTICALS, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| US-20100093735-A1 | CYTOKINE INHIBITORS | ITHERX PHARMACEUTICALS, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| EP-2152705-A1 | 9- (PYRAZOL- 3 -YL) - 9H- PURINE-2 -AMINE AND 3- (PYRAZ0L-3-YL) -3H-IMIDAZ0 [4, 5-B]PYRIDIN-5-AMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER | AstraZeneca AB (SE) | 2010-02-17 | — | — | EP | disclosed |
| EP-1670787-A4 | CYTOKINE INHIBITORS | KEMIA INC (US) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008135785-A1 | 9- (PYRAZOL- 3 -YL) - 9H- PURINE-2 -AMINE AND 3- (PYRAZ0L-3-YL) -3H-IMIDAZ0 [4, 5-B] PYRIDIN-5-AMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-11-13 | — | — | WO | disclosed |
| WO-2008083070-A1 | CRF1 RECEPTOR LIGANDS COMPRISING FUSED BICYCLIC HETEROARYL MOIETIES | NEUROGEN CORPORATION (US) | 2008-07-10 | — | — | WO | disclosed |
| EP-1670787-A2 | CYTOKINE INHIBITORS | Kemia, INC. (US) | 2006-06-21 | — | — | EP | disclosed |
| US-20050107399-A1 | Cytokine inhibitors | KEMIA, INC. | 2005-05-19 | — | — | US | disclosed |
| WO-2005023761-A2 | CYTOKINE INHIBITORS | KEMIA, INC. (US) | 2005-03-17 | — | — | WO | disclosed |
| US-6417185-B1 | HETEROCYCLIC ENZYME INHIBITORS | CHIRON CORPORATION | 2002-07-09 | — | — | US | disclosed |